Trisha Wise-Draper, MD, PhD, assistant professor, University of Cincinnati, discusses the quality of life (QOL) as a predictor of clinical outcome in patients with head and neck cancer (HNC).
Videos
Alexander Zukiwski, MD, CEO, Arno Therapeutics, Inc., discusses the efficacy of onapristone (ONA) in progesterone receptor (PR)-expressing tumors.
Yung-Jue Bang, MD, PhD, professor of medical oncology, College of Medicine, Seoul National University, president, Biomedical Research Institute, Seoul National University Hospital, discusses the clinical results for the treatment of pembrolizumab in patients with advanced gastric cancer.
Michael Manns, MD, chairman for the Department of Gastroenterology, Hepatology, and Endocrinology, Center of Internal Medicine, Hanover Medical School, Hanover, Germany, Vice President, United European Gastroenterology (UEG), discusses testing and treatment for Hepatitis C in patients with, as well as without, Hepatocellular carcinoma (HCC) liver cancer.
Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Safety and PK Results From an Ongoing Phase I-II Study of ONA in Patients With PR-Expressing Cancers
Paul Cottu, MD, MSc, medical oncologist, Institut Curie, Paris, discusses safety and pharmacokinetic (PK) results from phase I of an ongoing phase I-II study of onapristone (ONA) in patients with progesterone receptor (PR)-expressing cancers.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
2
Beyond SC Daratumumab: Emerging Therapeutic Approaches for Smoldering Myeloma
3
Poll: Vote on the Top Abstracts to Watch at ASH 2025
4
AQUILA Trial: SC Daratumumab Halves Risk of Progression to Active Myeloma
5
